{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Octapharma",
    "query": {
      "sponsor": "Octapharma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 53,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Octapharma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T16:17:17.696Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04376762",
      "title": "Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pediatric HD",
        "Bleeding"
      ],
      "interventions": [
        {
          "name": "Fibrinogen",
          "type": "DRUG"
        },
        {
          "name": "Cryoprecipitate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "Up to 24 Months"
      },
      "enrollment_count": 31,
      "start_date": "2021-10-26",
      "completion_date": "2023-05-01",
      "has_results": true,
      "last_update_posted_date": "2026-03-06",
      "last_synced_at": "2026-09-03T16:17:17.696Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04376762"
    },
    {
      "nct_id": "NCT01575756",
      "title": "Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Congenital Fibrinogen Deficiency",
        "Afibrinogenemia"
      ],
      "interventions": [
        {
          "name": "Octafibrin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Haemocomplettan® P or RiaSTAPTM",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2013-06",
      "completion_date": "2015-01",
      "has_results": true,
      "last_update_posted_date": "2018-03-09",
      "last_synced_at": "2026-09-03T16:17:17.696Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • New Hyde Park, New York",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01575756"
    },
    {
      "nct_id": "NCT02728752",
      "title": "Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dermatomyositis"
      ],
      "interventions": [
        {
          "name": "Octagam 10%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 95,
      "start_date": "2017-02-27",
      "completion_date": "2019-11-05",
      "has_results": true,
      "last_update_posted_date": "2021-12-23",
      "last_synced_at": "2026-09-03T16:17:17.696Z",
      "location_count": 17,
      "location_summary": "Huntington Beach, California • Los Angeles, California • Orange, California + 14 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Panama City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02728752"
    },
    {
      "nct_id": "NCT01602419",
      "title": "Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Von Willebrand Disease"
      ],
      "interventions": [
        {
          "name": "Patients using Wilate as standard of care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 120,
      "start_date": "2012-10",
      "completion_date": "2018-04",
      "has_results": true,
      "last_update_posted_date": "2021-01-19",
      "last_synced_at": "2026-09-03T16:17:17.696Z",
      "location_count": 4,
      "location_summary": "Torrance, California • Miami, Florida • Salt Lake City, Utah + 1 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01602419"
    },
    {
      "nct_id": "NCT02740335",
      "title": "Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Significant Bleeding Risk"
      ],
      "interventions": [
        {
          "name": "Octaplex",
          "type": "DRUG"
        },
        {
          "name": "Beriplex P/N (Kcentra)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 208,
      "start_date": "2017-06-08",
      "completion_date": "2022-02-23",
      "has_results": true,
      "last_update_posted_date": "2023-03-08",
      "last_synced_at": "2026-09-03T16:17:17.696Z",
      "location_count": 22,
      "location_summary": "Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02740335"
    },
    {
      "nct_id": "NCT02256917",
      "title": "Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Severe Haemophilia A"
      ],
      "interventions": [
        {
          "name": "Human cl rhFVIII",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 58,
      "start_date": "2015-05",
      "completion_date": "2018-09",
      "has_results": true,
      "last_update_posted_date": "2021-01-19",
      "last_synced_at": "2026-09-03T16:17:17.696Z",
      "location_count": 9,
      "location_summary": "Sacramento, California • Aurora, Colorado • Washington D.C., District of Columbia + 6 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02256917"
    },
    {
      "nct_id": "NCT04929236",
      "title": "Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pediatric Chronic Inflammatory Demyelinating Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "Panzyga",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 30,
      "start_date": "2023-10-01",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-09-03T16:17:17.696Z",
      "location_count": 6,
      "location_summary": "Birmingham, Alabama • Orange, California • Louisville, Kentucky + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04929236"
    },
    {
      "nct_id": "NCT01938378",
      "title": "Octaplas Pediatric Plasma Exchange Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Adverse Effects in the Therapeutic Use of Plasma Substitutes"
      ],
      "interventions": [
        {
          "name": "Octaplas™",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "2 Years to 20 Years"
      },
      "enrollment_count": 41,
      "start_date": "2015-04",
      "completion_date": "2019-01-27",
      "has_results": true,
      "last_update_posted_date": "2020-03-24",
      "last_synced_at": "2026-09-03T16:17:17.696Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • New Orleans, Louisiana + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01938378"
    },
    {
      "nct_id": "NCT01859754",
      "title": "Octagam 5% Versus Comparator Post Marketing Trial",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Primary Immune Deficiency Disorder"
      ],
      "interventions": [
        {
          "name": "Octagam 5%",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Other marketed IVIG product",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 623,
      "start_date": "2013-05-21",
      "completion_date": "2019-05-22",
      "has_results": false,
      "last_update_posted_date": "2019-06-10",
      "last_synced_at": "2026-09-03T16:17:17.696Z",
      "location_count": 27,
      "location_summary": "Granada Hills, California • Irvine, California • Los Angeles, California + 22 more",
      "locations": [
        {
          "city": "Granada Hills",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redlands",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01859754"
    },
    {
      "nct_id": "NCT04153422",
      "title": "IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Fiber Neuropathy",
        "Autoimmune Small Fiber Neuropathy",
        "Inflammatory Polyneuropathy",
        "Immune-Mediated Neuropathy"
      ],
      "interventions": [
        {
          "name": "Panzyga IVIG",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endeavor Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2023-12-15",
      "completion_date": "2028-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-09-03T16:17:17.696Z",
      "location_count": 1,
      "location_summary": "Glenview, Illinois",
      "locations": [
        {
          "city": "Glenview",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04153422"
    }
  ]
}